Advertisement

Topics

One trend that highlights current over-competitiveness – how quickly Ph3 H2H initiated vs new drugs: $NVS -$5B today as $JNJ Tremfya beats Cosentyx in psoriasis $AZN acalabrutinib vs $ABBV Ibrutinib CLL $MRK.DE PD-L1/TGF-β vs Keytruda 1L NSCLC $PFE Or

10:31 EST 7 Dec 2018 | Andy Biotech

One trend that highlights current over-competitiveness – how quickly Ph3 H2H initiated vs new drugs: -$5B today as Tremfya beats Cosentyx in psoriasis acalabrutinib vs Ibrutinib CLL PD-L1/TGF-β vs Keytruda 1L NSCLC Oral JAKi vs Dupi in AD

Original Article: One trend that highlights current over-competitiveness – how quickly Ph3 H2H initiated vs new drugs: $NVS -$5B today as $JNJ Tremfya beats Cosentyx in psoriasis $AZN acalabrutinib vs $ABBV Ibrutinib CLL $MRK.DE PD-L1/TGF-β vs Keytruda 1L NSCLC $PFE Or

NEXT ARTICLE

More From BioPortfolio on "One trend that highlights current over-competitiveness – how quickly Ph3 H2H initiated vs new drugs: $NVS -$5B today as $JNJ Tremfya beats Cosentyx in psoriasis $AZN acalabrutinib vs $ABBV Ibrutinib CLL $MRK.DE PD-L1/TGF-β vs Keytruda 1L NSCLC $PFE Or"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Psoriasis
Psoriasis is a common skin condition affecting 2-3% of the population of the United Kingdom, where the skins replacement process is sped taking 2-6 days instead of the usual 21 - 28 days for the replacement of skin cells. Patients experience an accumulat...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...